ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction

Molecular and Cellular Biology

Volumn 34, Issue 23, 2014, Pages 4232-4243

  Perry, Marie Claude ^a,b   Dufour, Catherine R ^a   Eichner, Lillian J ^a,b,c   Tsang, David W K ^a,b   Deblois, Geneviève ^a,b   Muller, William J ^a,b   Giguère, Vincent ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRASTUZUMAB; ANTINEOPLASTIC AGENT; E2F1 PROTEIN, MOUSE; ERBB2 PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART DISEASE; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; ADAPTATION; ANIMAL; BIOSYNTHESIS; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; ECHOCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION PROFILING; GENE TARGETING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEART; HEART STROKE VOLUME; IMMUNOLOGY; METABOLISM; PHYSIOLOGICAL STRESS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIOMEGALY; CELLS, CULTURED; DOXORUBICIN; E2F1 TRANSCRIPTION FACTOR; ECHOCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION PROFILING; GENE KNOCK-IN TECHNIQUES; HEART; HUMANS; MICE; MYOCYTES, CARDIAC; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; STROKE VOLUME; TRASTUZUMAB;

EID: 84909619835     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00895-14     Document Type: Article

References (35)

1. Yarden Y, Pines G. 2012. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12:553-563. http://dx.doi.org/10.1038 /nrc3309.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792. http://dx.doi.org/10.1056/NEJM200103153441101.
3. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398. http://dx.doi.org/10.1038/378394a0.
4. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. 2002. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20:1215-1221. http://dx.doi.org/10 .1200/JCO.20.5.1215.
5. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. 2005. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23:7820-7826. http://dx.doi.org/10.1200/JCO.2005.13.300.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Jr, Chien KR, Lee KF. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:459-465. http://dx.doi.org/10.1038/nm0502-459.
7. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, Garratt AN. 2002. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 99:8880-8885. http://dx.doi.org/10 .1073/pnas.122249299.
8. Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF. 1982. Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J. Clin. Invest. 70:1300- 1305. http://dx.doi.org/10.1172/JCI110729.
9. Gunther S, Grossman W. 1979. Determinants of ventricular function in pressure-overload hypertrophy in man. Circulation 59:679-688. http: //dx.doi.org/10.1161/01.CIR.59.4.679.
10. Heineke J, Molkentin JD. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell. Biol. 7:589-600. http://dx.doi.org/10.1038/nrm1983.
11. Chan R, Hardy WR, Dankort D, Laing MA, Muller WJ. 2004. Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development 131:5551-5560. http: //dx.doi.org/10.1242/dev.01425.
12. Al-Shahrour F, Minguez P, Tarraga J, Montaner D, Alloza E, Vaquerizas JM, Conde L, Blaschke C, Vera J, Dopazo J. 2006. BABELOMICS: a systems biology perspective in the functional annotation of genomescale experiments. Nucleic Acids Res. 34:W472-W476. http://dx.doi.org /10.1093/nar/gkl172.
13. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J. 2005. BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res. 33:W460-W464. http://dx.doi.org/10.1093/nar/gki456.
14. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguere V. 2007. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRα and γ. Cell Metab. 5:345-356. http://dx.doi.org/10.1016/j.cmet.2007.03.007.
15. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, Loh YH, Yeo HC, Yeo ZX, Narang V, Govindarajan KR, Leong B, Shahab A, Ruan Y, Bourque G, Sung WK, Clarke ND, Wei CL, Ng HH. 2008. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133:1106- 1117. http://dx.doi.org/10.1016/j.cell.2008.04.043.
16. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 25:1754-1760. http://dx.doi .org/10.1093/bioinformatics/btp324.
17. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS. 2008. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9:R137. http://dx.doi.org/10 .1186/gb-2008-9-9-r137.
18. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineagedetermining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38:576-589. http://dx.doi .org/10.1016/j.molcel.2010.05.004.
19. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. 2006. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J. Clin. Oncol. 24:4107- 4115. http://dx.doi.org/10.1200/JCO.2005.04.9551.
20. Cloud JE, Rogers C, Reza TL, Ziebold U, Stone JR, Picard MH, Caron AM, Bronson RT, Lees JA. 2002. Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo. Mol. Cell. Biol. 22:2663-2672. http://dx .doi.org/10.1128/MCB.22.8.2663-2672.2002.
21. Weijts BG, Bakker WJ, Cornelissen PW, Liang KH, Schaftenaar FH, Westendorp B, de Wolf CA, Paciejewska M, Scheele CL, Kent L, Leone G, Schulte-Merker S, de Bruin A. 2012. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. EMBO J. 31:3871-3884. http://dx.doi.org/10.1038/emboj.2012.231.
22. Zhou J, Wu M, Xu S, Cheng M, Ding C, Liu Y, Yan H, Biyashev D, Kishore R, Qin G. 2013. Contrasting Roles of E2F2 and E2F3 in Cardiac Neovascularization. PLoS One 8:e65755. http://dx.doi.org/10.1371 /journal.pone.0065755.
23. Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R. 1999. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp. Mol. Pathol. 67:15-25. http://dx.doi.org/10.1006/exmp.1999.2266.
24. Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI. 1995. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat. Med. 1:644-648. http://dx .doi.org/10.1038/nm0795-644.
25. Rachmin I, Tshori S, Smith Y, Oppenheim A, Marchetto S, Kay G, Foo RS, Dagan N, Golomb E, Gilon D, Borg JP, Razin E. 2014. Erbin is a negative modulator of cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 111:5902-5907. http://dx.doi.org/10.1073/pnas.1320350111.
26. Fernandez-Salguero PM, Ward JM, Sundberg JP, Gonzalez FJ. 1997. Lesions of aryl-hydrocarbon receptor-deficient mice. Vet. Pathol. 34:605-614. http://dx.doi.org/10.1177/030098589703400609.
27. Hannigan GE, Coles JG, Dedhar S. 2007. Integrin-linked kinase at the heart of cardiac contractility, repair, and disease. Circ. Res. 100:1408-1414. http://dx.doi.org/10.1161/01.RES.0000265233.40455.62.
28. Sibilia M, Wagner B, Hoebertz A, Elliott C, Marino S, Jochum W, Wagner EF. 2003. Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development 130:4515- 4525. http://dx.doi.org/10.1242/dev.00664.
29. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. 2009. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am. J. Physiol. Heart Circ. Physiol. 296:H1694-H1704. http://dx.doi.org/10 .1152/ajpheart.00908.2008.
30. 2 homeostasis by hypoxiainducible factor 1 alpha. Genes Dev. 12:149-162. http://dx.doi.org/10 .1101/gad.12.2.149.
31. Laustsen PG, Russell SJ, Cui L, Entingh-Pearsall A, Holzenberger M, Liao R, Kahn CR. 2007. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell. Biol. 27:1649-1664. http://dx.doi.org/10.1128/MCB.01110-06.
32. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T. 2000. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with agedependent cardiac toxicity. J. Biol. Chem. 275:22293-22299. http://dx.doi .org/10.1074/jbc.M000248200.
33. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, Li CK, Wong YO, Ng PC. 2006. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113:2211-2220. http://dx.doi.org/10.1161 /CIRCULATIONAHA.105.560250.
34. Gu R, Bai J, Ling L, Ding L, Zhang N, Ye J, Ferro A, Xu B. 2012. Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats. PLoS One 7:e31279. http://dx.doi.org/10.1371/journal.pone.0031279.
35. Catalucci D, Latronico MV, Ellingsen O, Condorelli G. 2008. Physiological myocardial hypertrophy: how and why? Front. Biosci. 13:312-324. http://dx.doi.org/10.2741/2681.